Background: Generalized pustular psoriasis (GPP) is a severe and disabling variant of psoriasis. The treatment of GPP is challenging, often characterized by side effects or unsatisfactory response. Etanercept is a tumor necrosis factor α blocking agent that demonstrated a consistent efficacy in the control of psoriasis. Objectives: We aimed to evaluate the efficacy and safety profile of etanercept at different dosages in GPP. Methods: Six patients affected by GPP, unresponsive to conventional treatment, received etanercept subcutaneously at the dosages of 25 and 50 mg biweekly for 48 weeks. Results: Our experience led to the observation that the administration of etanercept 50 mg biweekly is an effective dosage, characterized by good efficacy and rapidity of effect. Patients who were continuously treated at this dosage for 24 weeks presented stable conditions and long-term maintenance until week 48 even after a dose reduction to 25 mg. Conclusion: We demonstrated a good and durable efficacy of etanercept in patients affected by GPP.

Keywords:
Biologics, Etanercept, Pustular psoriasis, Tumor necrosis factor α
1.
Christophers E, Mrowietz U: Psoriasis; in Freedberg IM, Eisen AZ, Wolff K, Frank Austen K, Goldsmith LA, Katz SI (eds): Fitzpatrick’s Dermatology in General Medicine, ed 6. New York, McGraw Hill, 2003, pp 407–427.
2.
Umezawa Y, Ozawa A, Kawasima T, Shimizu H, Terui T, Tagami H, Ikeda S, Ogawa H, Kawada A, Tezuka T, Igarashi A, Harada S: Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res 2003;295:S43–S54.
3.
Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R: A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627–1632.
4.
Leonardi CL, Powers JL, Matheson RT, Goffe GS, Zitnik R, Wang A, Gottlieb AB, Etanercept Psoriasis Study Group: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014–2022.
5.
Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group: A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304–1312.
6.
Alexis AF, Strober BE: Off-label dermatologic uses of anti-TNF-α therapies. J Cutan Med Surg 2005;9:296–302.
7.
Carrera C, Mascarò JM Jr, Moreno-Romero JA, Iranzo P, Palou J, Zamora E, Herrero C: Pyoderma vegetans associated with severe psoriatic arthritis: good response to etanercept. Dermatology 2007;214:77–81.
8.
Fredriksson T, Pettersson U: Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978;157:238–244
9.
Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK: Biology of tumor necrosis factor-α – implications for psoriasis. Exp Dermatol 2004;13:193–222.
10.
Costanzo A, Mazzotta A, Papoutsaki M, Nisticò S, Chimenti S: Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol 2005;152:187–189.
11.
Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S: Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol 2006;155:156–159.
12.
Lisby S, Gniadecki R: Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. Acta Derm Venereol 2004;84:247–248.
13.
Newland MR, Weinstein A, Kerdel FA: Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002;41:449–452.
14.
Trent JT, Kerdel FA: Successful treatment of Von Zumbusch pustular psoriasis with infliximab. J Cutan Med Surg 2004;8:224–228.
15.
Weisenseel P, Prinz JC: Sequential use of infliximab and etanercept in generalized pustular psoriasis. Cutis 2006;78:197–199.
16.
Kazinski K, Joyce KM, Hodson D: The successful use of etanercept in combination therapy for treatment of acrodermatitis continua of Hallopeau. J Drugs Dermatol 2005;4:360–364.
17.
Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G, Nestle FO: Generalized pustular psoriasis induced by cyclosporin A withdrawal responding to the tumor necrosis factor alpha inhibitor etanercept. Dermatology 2002;205:213–216.
18.
Pereira TM, Vieira AP, Fernandes JC, Antunes H, Basto AS: Anti-TNF-alpha therapy in childhood pustular psoriasis. Dermatology 2006;213:350–352.
19.
Heymann WR: Tumor necrosis factor inhibitor-induced pustular psoriasis. J Am Acad Dermatol 2007;56:327–329.
20.
Goiriz R, Dauden E, Perez-Gals S, Guhl G, Garcia-Diez A: Flare and change of psoriasis morphology during the course of treatment with tumor necrosis factor blockers. Clin Exp Dermatol 2007;32:176–179.
21.
De Gannes GC, Goreishi M, Pope J, Russel A, Bell D, Adams S, Shojania K, Martinka M, Dutz JP: Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223–231.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.